Bristol Myers angles Breyanzi for another blood cancer as it works to close Gilead's CAR-T lead

With another trial win, Bristol Myers Squibb is touting Breyanzi as the CD19-directed CAR-T therapy with positive readouts in the most cancer types.

The latest readout positions Breyanzi for a potential foray into marginal zone lymphoma (MZL), for which none of the existing CAR-T therapies are approved by the FDA.